Findings from a study conducted by Dr. Chris Gaj, Vice President at Research Partnership, have been published in Clinical Genitourinary Cancer.
The study, led by Johnson and Johnson, explored using real world evidence collected by patient records from physicians to examine the impact of genetic mutations on response to therapy in urothelial carcinoma.
Discover more about how we help to shape the future of oncology treatments here.
Jump to a slide with the slide dots.
Stephanie Tortell Announced as Candidate for ISMPP Chair-Elect 2025
At Inizio, we are proud to support leaders who exemplify excellence, integrity, and a deep commitment to advancing healthcare communications.
Read moreShowcasing innovation at MAPS EMEA 2025.
We are excited to announce that Inizio will be exhibiting at the MAPS EMEA Annual Meeting in London, from 12-14th May 2025.
Read moreReimagining a healthier future: A message from our Head of Sustainability
Explore Inizio’s 2024 sustainability report from Head of ESG Dervala Leahy, covering Net Zero progress, CSRD readiness, and ESG strategy.
Read more